文献速递血栓与止血

直接口服抗凝药治疗肝素诱导的血小板减少症:哈密尔顿经验更新及文献综述

Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review.
PubMed 文献 · Blood · 2017-06-23

该研究报道了加拿大哈密尔顿自2015年1月1日起使用利伐沙班治疗血清学确诊的肝素诱导的血小板减少症(HIT)的持续经验,并综述了直接口服抗凝药(DOAC)治疗HIT的文献。10例急性HIT患者接受利伐沙班治疗均无新发、进展或复发性血栓形成;文献综述结合新数据发现,急性HIT期间接受利伐沙班治疗的患者血栓发生率为46例中1例(2.2%;95%CI,0.4%-11.3%),大出血为46例中0例。

要点

  • 利伐沙班治疗急性HIT患者46例中血栓发生率2.2%(95%CI,0.4%-11.3%),大出血0例。
  • 阿哌沙班(n=12)和达比加群(n=11)在较小样本中观察到相似结局。
  • DOAC为部分HIT患者提供简化管理,利伐沙班经验最多。

核心结论

  • 支持DOAC用于急性HIT的有效性和安全性证据正在增加,其中利伐沙班的报告经验最多。

研究设计与样本

  • 研究报道了加拿大安大略省哈密尔顿自2015年1月1日起使用利伐沙班治疗血清学确诊HIT(4Ts评分≥4分;血小板因子4/肝素免疫分析阳性;血清素释放试验阳性)的持续经验,并进行了DOAC(利伐沙班、阿哌沙班、达比加群、艾多沙班)治疗HIT的文献综述。
  • 分析聚焦于因急性HIT接受DOAC治疗的患者,分为原发治疗(A组)或继发治疗(B组;初始使用非DOAC/非肝素抗凝药,在HIT相关血小板减少期间转换为DOAC)。
  • 主要终点为急性HIT的DOAC治疗期间发生客观记录的血栓形成。

主要发现

  • 哈密尔顿10例接受利伐沙班治疗的急性HIT患者均恢复,无新发、进展或复发性血栓形成。
  • 文献综述加新数据:急性HIT期间接受利伐沙班治疗的患者血栓发生率为46例中1例(2.2%;95%CI,0.4%-11.3%),A组n=25,B组n=21;大出血为46例中0例。
  • 阿哌沙班(n=12)和达比加群(n=11)在较小样本中观察到相似结局。
  • 一例持续性(自身免疫性)HIT(血小板恢复>2个月,血清诱导的非肝素依赖性血清素释放呈反向平行减弱)伴HIT相关血栓形成,成功接受门诊利伐沙班管理。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Direct oral anticoagulants (DOACs) are attractive options for treatment of heparin-induced thrombocytopenia (HIT). We report our continuing experience in Hamilton, ON, Canada, since January 1, 2015 (when we completed our prospective study of rivaroxaban for HIT), using rivaroxaban for serologically confirmed HIT (4Ts score ≥4 points; positive platelet factor 4 [PF4]/heparin immunoassay, positive serotonin-release assay). We also performed a literature review of HIT treatment using DOACs (rivaroxaban, apixaban, dabigatran, edoxaban). We focused on patients who received DOAC therapy for acute HIT as either primary therapy (group A) or secondary therapy (group B; initial treatment using a non-DOAC/non-heparin anticoagulant with transition to a DOAC during HIT-associated thrombocytopenia). Our primary end point was occurrence of objectively documented thrombosis during DOAC therapy for acute HIT. We found that recovery without new, progressive, or recurrent thrombosis occurred in all 10 Hamilton patients with acute HIT treated with rivaroxaban. Data from the literature review plus these new data identified a thrombosis rate of 1 of 46 patients (2.2%; 95% CI, 0.4%-11.3%) in patients treated with rivaroxaban during acute HIT (group A, n = 25; group B, n = 21); major hemorrhage was seen in 0 of 46 patients. Similar outcomes in smaller numbers of patients were observed with apixaban (n = 12) and dabigatran (n = 11). DOACs offer simplified management of selected patients, as illustrated by a case of persisting (autoimmune) HIT (>2-month platelet recovery with inversely parallel waning of serum-induced heparin-independent serotonin release) with successful outpatient rivaroxaban management of HIT-associated thrombosis. Evidence supporting efficacy and safety of DOACs for acute HIT is increasing, with the most experience reported for rivaroxaban.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Warkentin TE, Pai M, Linkins LA, et al. Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review. Blood. 2017. PMID: 28646118. doi:10.1182/blood-2017-04-778993

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。